Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) has announced a landmark FDA approval for TARPEYO (budesonide) delayed release capsules, aimed at reducing kidney function loss in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. Initially granted accelerated approval in December 2021, TARPEYO now stands as the first fully FDA-approved treatment […]
Swedish pharmaceutical company Calliditas Therapeutics has initiated the Phase 3 NEFIGARD trial to evaluate its lead drug candidate, Nefecon, for treating IgA nephropathy (IgAN), commonly known as Berger’s disease. The NEFIGARD trial marks a significant step for Calliditas Therapeutics as it begins enrolling patients for a late-stage study designed to assess the effectiveness of Nefecon […]
